VTRS PDUFA decision: Sunday, December 27, 2026

…n for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of December 27, 2026. • The Company signed a distribution agreement with Accord Healthcare to commercialize three biosimilar products (filgrastim,

Dates are sourced from official registries and filings and can change — estimated dates (marked ~) slip routinely. This page updates automatically when the source registry moves the date. Research information only, not investment advice.